PMID- 15820944
OWN - NLM
STAT- MEDLINE
DCOM- 20060525
LR  - 20171116
IS  - 1592-8721 (Electronic)
IS  - 0390-6078 (Linking)
VI  - 90
IP  - 4
DP  - 2005 Apr
TI  - CD44v6, a target for novel antibody treatment approaches, is frequently expressed 
      in multiple myeloma and associated with deletion of chromosome arm 13q.
PG  - 489-93
AB  - BACKGROUND AND OBJECTIVES: Despite recent advances in the treatment of multiple 
      myeloma (MM), this disease remains incurable in the majority of patients. 
      Therefore, innovative treatment strategies are mandatory. Bivatuzumab mertansine 
      is a novel cytotoxic immunoconjugate specifically targeting the CD44 splice 
      variant CD44v6. To investigate the applicability of this compound to clonal 
      plasma cell disorders, we analyzed CD44v6 expression on malignant plasma cells 
      from patients with multiple myeloma. DESIGN AND METHODS: Bone marrow samples from 
      57 patients with monoclonal gammopathy of undetermined significance (MGUS), MM, 
      and plasma cell leukemia (PCL) were examined for CD44v6 expression by using flow 
      cytometry (FACS) analysis. In addition, all samples were investigated by 
      fluorescence in situ hybridization (FISH) with a specific probe for the 
      chromosomal band 13q14. RESULTS: In only 1 of 16 cases (6%) with MGUS and 1 out 
      of 6 cases (17%) with stage I MM were plasma cells CD44v6 positive. In contrast, 
      43% of the cases with stage II/III MM or PCL expressed CD44v6. In these cases, 
      CD44v6 expression was significantly correlated with chromosome 13q14 deletion as 
      determined by FISH (p=0.02). INTERPRETATION AND CONCLUSIONS: CD44v6 is frequently 
      expressed in advanced, high-risk MM. CD44v6 expression correlates with 
      chromosomal band 13q14 deletions, a well-known risk factor in MM. These results 
      suggest that this epitope is a potential new target for monoclonal antibodies 
      such as bivatuzumab mertansine.
FAU - Liebisch, Peter
AU  - Liebisch P
AD  - Dept. of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
FAU - Eppinger, Susanne
AU  - Eppinger S
FAU - Schopflin, Christine
AU  - Schopflin C
FAU - Stehle, Gerd
AU  - Stehle G
FAU - Munzert, Gerd
AU  - Munzert G
FAU - Dohner, Hartmut
AU  - Dohner H
FAU - Schmid, Mathias
AU  - Schmid M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Haematologica
JT  - Haematologica
JID - 0417435
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CD44v6 antigen)
RN  - 0 (Glycoproteins)
RN  - 0 (Hyaluronan Receptors)
SB  - IM
CIN - Haematologica. 2005 Apr;90(4):436-7. PMID: 15820931
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - *Chromosome Deletion
MH  - Chromosomes, Human, Pair 13/*genetics
MH  - Female
MH  - Glycoproteins/*immunology
MH  - Humans
MH  - Hyaluronan Receptors/*immunology
MH  - Leukemia, Plasma Cell/drug therapy/genetics/immunology
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/*genetics/*immunology
MH  - Paraproteinemias/drug therapy/genetics/immunology
MH  - Tumor Burden/immunology
EDAT- 2005/04/12 09:00
MHDA- 2006/05/26 09:00
CRDT- 2005/04/12 09:00
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2006/05/26 09:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
PST - ppublish
SO  - Haematologica. 2005 Apr;90(4):489-93.